Although the dysregulated expression of MYEOV in cancer patients has been associated with its tumorigenic properties, the molecular mechanisms underlying MYEOV-mediated tumorigenesis, particularly in PDAC, remain largely unknown. This evidence concerns the gene MYEOV and cancer.